291 related articles for article (PubMed ID: 31095914)
1. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
[TBL] [Abstract][Full Text] [Related]
2. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
4. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
6. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
7. Targeted multidrug delivery system to overcome chemoresistance in breast cancer.
Tang Y; Soroush F; Tong Z; Kiani MF; Wang B
Int J Nanomedicine; 2017; 12():671-681. PubMed ID: 28176940
[TBL] [Abstract][Full Text] [Related]
8. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
9. A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance.
Guo L; Xu Y; Zhou A; Zhang L; Sun L; Gao Y; Chen J; Shan X; Zhang J; Ge J; An X; Liu X; Zhang Y; Ning X
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110403. PubMed ID: 31923941
[TBL] [Abstract][Full Text] [Related]
10. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
11. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
12. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
13. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
[TBL] [Abstract][Full Text] [Related]
14. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
15. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal.
Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG
ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
[TBL] [Abstract][Full Text] [Related]
17. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
18. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
Li X; Jia X; Niu H
Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]